Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2018

Open Access 01-12-2018 | Research

Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus

Authors: Chen-Wei Pan, Shan Wang, Cai-Lian Xu, E. Song

Published in: Diabetology & Metabolic Syndrome | Issue 1/2018

Login to get access

Abstract

Background

To explore the associations of glycemic and blood pressure (BP) control with diabetic retinopathy (DR), with special focus on whether different combinations of categories of these two interventions are additive.

Methods

A community-based survey including 913 patients with known type-2 diabetes mellitus (T2DM) was conducted in Suzhou, China. Retinal photographs were graded for the presence of DR using the Airlie House classification system. BP and blood hemoglobin A1c (HbA1C) levels were measured by standardized protocols. Binary logistic regression models were established to examine the associations of risk factors with DR.

Results

The overall prevalence of any DR was 18.0% [95% confidence interval (95% CI) 15.5–20.6%] in this population. Stratified by conventional control thresholds, lower levels of either systolic blood pressure (SBP, < 140 mmHg) or HbA1C (< 7.0%) were not significantly associated with decreased susceptibility to DR, while patients simultaneously with lower HbA1C and SBP levels demonstrated 43% reduced likelihood of developing DR [adjusted odds ratio (OR) = 0.57, 95% CI 0.33–0.99, P = 0.045)], comparing with those with both higher levels of HbA1C (≥ 7.0%) and SBP (≥ 140 mmHg). Meanwhile, the group achieved intensive HbA1C (< 6.5%) and SBP (< 120 mmHg) control goals were found to have the smallest OR, but failed in yielding statistical significance (P = 0.10).

Conclusions

In this community-based DR screening study of Chinese adults with T2DM, combination but not individual of lower SBP (< 140 mmHg) and HbA1C (< 7.0%) levels, were suggested to be associated with a significantly reduced likelihood of having DR.
Literature
1.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed
2.
go back to reference Xie X, Xu L, Jonas J, Wang Y. Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study. Eur J Ophthalmol. 2009;19(1):91.CrossRefPubMed Xie X, Xu L, Jonas J, Wang Y. Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study. Eur J Ophthalmol. 2009;19(1):91.CrossRefPubMed
3.
go back to reference Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8(1):1.CrossRef Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8(1):1.CrossRef
4.
go back to reference Ruta L, Magliano D, LeMesurier R, Taylor H, Zimmet P, Shaw J. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med. 2013;30(4):387–98.CrossRefPubMed Ruta L, Magliano D, LeMesurier R, Taylor H, Zimmet P, Shaw J. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med. 2013;30(4):387–98.CrossRefPubMed
5.
go back to reference Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.CrossRefPubMed Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.CrossRefPubMed
6.
go back to reference Song P, Yu J, Chan KY, Theodoratou E, Rudan I. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018;8(1):010803.CrossRefPubMedCentralPubMed Song P, Yu J, Chan KY, Theodoratou E, Rudan I. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018;8(1):010803.CrossRefPubMedCentralPubMed
8.
go back to reference Tung TH, Shih HC, Chen SJ, Chou P, Liu CM, Liu JH. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol. 2008;18(5):225–33.CrossRefPubMedCentralPubMed Tung TH, Shih HC, Chen SJ, Chou P, Liu CM, Liu JH. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol. 2008;18(5):225–33.CrossRefPubMedCentralPubMed
9.
go back to reference Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond). 2007;21(4):465–71.CrossRef Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond). 2007;21(4):465–71.CrossRef
10.
go back to reference Clark A, Morgan WH, Kain S, Farah H, Armstrong K, Preen D, Semmens JB, Yu DY. Diabetic retinopathy and the major causes of vision loss in Aboriginals from remote Western Australia. Clin Exp Ophthalmol. 2010;38(5):475–82.CrossRefPubMed Clark A, Morgan WH, Kain S, Farah H, Armstrong K, Preen D, Semmens JB, Yu DY. Diabetic retinopathy and the major causes of vision loss in Aboriginals from remote Western Australia. Clin Exp Ophthalmol. 2010;38(5):475–82.CrossRefPubMed
11.
go back to reference Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–63.CrossRefPubMed Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–63.CrossRefPubMed
12.
13.
go back to reference Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446–55.CrossRefPubMedCentralPubMed Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446–55.CrossRefPubMedCentralPubMed
14.
go back to reference Xu J, Wei WB, Yuan MX, Yuan SY, Wan G, Zheng YY, Li YB, Wang S, Xu L, Fu HJ, et al. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina. 2012;32(2):322–9.CrossRefPubMed Xu J, Wei WB, Yuan MX, Yuan SY, Wan G, Zheng YY, Li YB, Wang S, Xu L, Fu HJ, et al. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina. 2012;32(2):322–9.CrossRefPubMed
15.
go back to reference Stratton I, Cull C, Adler A, Matthews D, Neil H, Holman R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761–9.CrossRefPubMed Stratton I, Cull C, Adler A, Matthews D, Neil H, Holman R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761–9.CrossRefPubMed
16.
go back to reference Gerstein HC, Elgar FJ. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–9.CrossRef Gerstein HC, Elgar FJ. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–9.CrossRef
17.
go back to reference Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ Clin Res. 1998;317(7160):703–13.CrossRef Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ Clin Res. 1998;317(7160):703–13.CrossRef
18.
go back to reference Patel A, Macmahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Neth Heart J. 2007;370(1):829–40. Patel A, Macmahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Neth Heart J. 2007;370(1):829–40.
19.
20.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef
21.
go back to reference Group AC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;2008(358):2560–72. Group AC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;2008(358):2560–72.
22.
go back to reference Zoungas S, De Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes new results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–74.CrossRefPubMedCentralPubMed Zoungas S, De Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes new results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–74.CrossRefPubMedCentralPubMed
23.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed
24.
go back to reference Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30.CrossRefPubMedCentralPubMed Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30.CrossRefPubMedCentralPubMed
25.
go back to reference Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.CrossRefPubMedCentralPubMed Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.CrossRefPubMedCentralPubMed
26.
go back to reference Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–15.CrossRefPubMed Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–15.CrossRefPubMed
27.
go back to reference Ramsay LE, Williams B, Johnston GD, Macgregor GA, Poston L, Potter JF, Poulter NR. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ Clin Res. 1999;319(7210):630–5.CrossRef Ramsay LE, Williams B, Johnston GD, Macgregor GA, Poston L, Potter JF, Poulter NR. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ Clin Res. 1999;319(7210):630–5.CrossRef
28.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.CrossRefPubMed
29.
go back to reference Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.CrossRefPubMed Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.CrossRefPubMed
30.
go back to reference Ismailbeigi F, Craven TE, O’Connor PJ, Karl D, Callesescandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 2012;81(6):586–94.CrossRef Ismailbeigi F, Craven TE, O’Connor PJ, Karl D, Callesescandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 2012;81(6):586–94.CrossRef
31.
go back to reference Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8.CrossRefPubMedCentralPubMed Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8.CrossRefPubMedCentralPubMed
32.
go back to reference Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.CrossRefPubMed Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.CrossRefPubMed
33.
go back to reference Pan CW, Wang S, Qian DJ, Xu C, Song E. Prevalence, awareness, and risk factors of diabetic retinopathy among adults with known type 2 diabetes mellitus in an urban community in China. Ophthalmic Epidemiol. 2017;24(3):188–94.CrossRefPubMed Pan CW, Wang S, Qian DJ, Xu C, Song E. Prevalence, awareness, and risk factors of diabetic retinopathy among adults with known type 2 diabetes mellitus in an urban community in China. Ophthalmic Epidemiol. 2017;24(3):188–94.CrossRefPubMed
35.
go back to reference Song E, Qian DJ, Wang S, Xu C, Pan CW. Refractive error in Chinese with type 2 diabetes and its association with glycaemic control. Clin Exp Optom. 2018;101(2):213–9.CrossRefPubMed Song E, Qian DJ, Wang S, Xu C, Pan CW. Refractive error in Chinese with type 2 diabetes and its association with glycaemic control. Clin Exp Optom. 2018;101(2):213–9.CrossRefPubMed
36.
37.
go back to reference Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5 Suppl):786–806. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5 Suppl):786–806.
38.
go back to reference Rudnisky CJ, Wong BK, Virani H, Tennant MTS. Risk factors for progression of diabetic retinopathy in Alberta First Nations communities. Can J Ophthalmol. 2017;52(Suppl 1):S19–29.CrossRefPubMed Rudnisky CJ, Wong BK, Virani H, Tennant MTS. Risk factors for progression of diabetic retinopathy in Alberta First Nations communities. Can J Ophthalmol. 2017;52(Suppl 1):S19–29.CrossRefPubMed
39.
go back to reference Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–68.CrossRefPubMed Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–68.CrossRefPubMed
40.
go back to reference Rodrigues TC, Canani LH, Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. Diabetes Res Clin Pract. 2010;87(2):240–5.CrossRefPubMed Rodrigues TC, Canani LH, Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. Diabetes Res Clin Pract. 2010;87(2):240–5.CrossRefPubMed
41.
go back to reference Dosso AA, Leuenberger PM, Rungger-Brandle E. Remodeling of retinal capillaries in the diabetic hypertensive rat. Investig Ophthalmol Vis Sci. 1999;40(10):2405–10. Dosso AA, Leuenberger PM, Rungger-Brandle E. Remodeling of retinal capillaries in the diabetic hypertensive rat. Investig Ophthalmol Vis Sci. 1999;40(10):2405–10.
42.
go back to reference Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37(1):32–5.CrossRefPubMed Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37(1):32–5.CrossRefPubMed
43.
go back to reference Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia. 1999;42(8):995–8.CrossRefPubMed Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia. 1999;42(8):995–8.CrossRefPubMed
44.
go back to reference Wang Q, Pfister F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y, Hammes HP. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia. 2010;53(6):1227–38.CrossRefPubMed Wang Q, Pfister F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y, Hammes HP. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia. 2010;53(6):1227–38.CrossRefPubMed
45.
46.
go back to reference Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–93.CrossRefPubMed Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–93.CrossRefPubMed
47.
go back to reference Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32(6):533–41.CrossRefPubMed Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32(6):533–41.CrossRefPubMed
48.
go back to reference Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov. 2009;8(5):417–29.CrossRefPubMedCentralPubMed Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov. 2009;8(5):417–29.CrossRefPubMedCentralPubMed
Metadata
Title
Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus
Authors
Chen-Wei Pan
Shan Wang
Cai-Lian Xu
E. Song
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2018
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-018-0377-7

Other articles of this Issue 1/2018

Diabetology & Metabolic Syndrome 1/2018 Go to the issue